AdAlta appoints Dr Dallas Hartman as Chief Operating Officer
AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, is pleased to announce the appointment of experienced executive, Dr Dallas Hartman to the role of Chief Operating Officer. Dr Hartman will bring…
Read MorePatrys and Garvan Institute of Medical Research Awarded Grant
Patrys Limited (ASX: PAB), a clinical stage biotechnology company and Sydney’s Garvan Institute of Medical Research (Garvan) have recently finalized the terms of a Federal Government Innovation Connections grant to support research within the PATDX1 program. The Garvan…
Read MoreNew US patent for Patrys PAT-LM1
Patrys (ASX:PAB), a clinical stage biotechnology company, has been granted a US patent for its anti-cancer pre-clinical candidate PAT-LM1. The US Patent Office has issued correspondence confirming the grant of a key patent in the PAT-LM1 family, patent…
Read MoreUniversal Biosensors receives $7.5M under the R&D Tax Incentive
Universal Biosensors (ASX:UBI) today announced it has received $7.5M in cash under the R&D Tax Incentive for the 2016 financial year. The R&D Tax Incentive is an Australian Government program developed to assist eligible businesses recover some of…
Read MoreMedical Device Industry Sign Historic Agreement to Reduce Health Fund Premiums
The Medical Technology Association of Australia (MTAA) has signed a four-year Agreement with the Federal Government which will deliver certainty and stability to the industry and will help lower Private Health Insurance (PHI) premiums for Australians. The Agreement,…
Read MoreGKC names John Schellhorn new President and CEO
GKC announced today that it has appointed John Schellhorn as its new President and CEO. Schellhorn will also be joining the company’s Board of Directors. Schellhorn joins GKC with a proven track record to spearhead the company’s accelerated…
Read MoreStarpharma and Peter Mac Cancer Centre awarded DEP® Grant
Starpharma (ASX: SPL, OTCQX: SPHRY) and Peter MacCallum Cancer Centre (Peter Mac) have been awarded a further Federal Government Innovation Connections grant to support innovative research within Starpharma’s DEP® oncology program. Starpharma’s proprietary DEP® dendrimer platform improves efficacy…
Read MoreLBT Receives $4.2 Million in R&D Incentives
Australian medical technology company LBT Innovations Limited (ASX:LBT) has received an R&D Incentive, net of income tax payable, of $3.98 Million for the financial year ended 30 June 2017. In addition, LBT has also received $0.22 Million for…
Read MoreBioMelbourne Network submission to the Policy Consultation Paper – Visa Simplification: Transforming Australia’s Visa System
October 2017 “Australia’s visa system must remain globally competitive to attract talent to build future industries and transition to a knowledge-led economy” Health is a global market and access to global talent is critical for healthcare innovation. Companies…
Read More
